Antibody Stories

Market Dynamics: The monoclonal antibody therapeutics market, projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, demonstrates a ro...

This antibody is a mouse monoclonal antibody that binds specifically to CD39, and it can neutralize the bioactivity of CD39.

The global antibody discovery market is anticipated to reach a valuation of US$ 7,652.2 million in 2024, driven by the increasing incidence of chronic diseases. The tren...

A monoclonal antibody specifically binds to human B7.1 antigen and is capable of inhibiting the binding of B7.1 to a CD28 receptor and is not capable of inhibiting the b...

Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH...

macrophage m1: Creative Biolabs has organized a staff of top-class scientists who have substantial experience and expertise in macrophage therapeutics development. Our o...

Immune Checkpoint Peptide Development: Regarding drug development, peptides have many advantages in various aspects compared with therapeutic antibodies and small molecu...

Creative Biolabs can offer the unique monoclonal human antibody production service with ethics approval. Taking advantage of the advanced phage display technology, our s...

Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra a...